The NCI wants to encourage clinical trial investigators to review data from their completed clinical trials and treating oncologists to look back in their patient records to identify potential cases of exceptional responses and submit them for consideration in the initiative.
As part of its Exceptional Responders Initiative, the National Cancer Institute (NCI) continues to reach out to the oncology community.
The initiative is collecting cases in which patients with any cancer had dramatic and long-lasting responses to standard and experimental treatments that were not seen in similar patients who received the same treatment.
By studying tissue, clinical, and genomic data from these patients, NCI scientists hope to learn whether such exceptional responses can provide broader insights into the genetic mechanisms that underlie such responses and suggest therapeutic options that weren’t previously apparent, explained Barbara Conley, MD, of NCI’s Division of Cancer Treatment and Diagnosis.
Link to the complete article on NCI's website:
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen